Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Comparative efficacy of amiodarone with ivabradin combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation recurrence in pa- tients with left ventricular diastolic dysfunction

https://doi.org/10.20996/1819-6446-2015-11-5-483-488

Full Text:

Abstract

Aim. To study the efficacy of use of amiodarone with ivabradine combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation (AF) recurrence in patients (pts) with left ventricular diastolic dysfunction (LVDD) after conversion to sinus rhythm.
Material and methods. 65 patients (40 males, 25 females) aged 53±8 years with persistent AF and LVDD were included into the study and randomized into 3 groups to receive ivabradine and amiodarone (22 pts), bisoprolol and amiodarone (22 pts) or amiodarone alone (21 pts). Left atrium (LA) volume indices, LA longitudinal strain rate (LASR) in systole, LV mass index, mean heart rate (HR), 24-hour HR variability and the incidence of AF by 96 h ECG monitoring were measured after the titration period, and after 3 and 6 months of follow-up. 

Results. After 6 months of follow-up group 1 revealed significantly lower maximum LA volume index (21.3±2.4 vs 25.2±3.0 and 28.7±3.6 ml/m2 in the 2nd and control groups, respectively), P-wave LA volume index (15.3±3.5 versus 18.1±3.8 and 20.4±4.0 ml/m2 in the 2nd and control groups, respectively), and LA systolic volume index (7.3±1.2 versus 9.4±1.6 and 9.6±1.7 ml/m2 in 2nd and control groups, respectively). The incidence of side effects in group 1 was significantly less than that in group 2 and was not different compared with control group. 

Conclusion. Ivabradine and amiodarone combination provides better prevention of AF recurrence and less side-effects in pts with LVDD and persistent AF after sinus rhythm restoration as compared with bisoprolol and amiodarone combination, it also reduces LA maximum, conduit and systolic volumes, and increases LASR.

About the Authors

K. G. Adamyan
Research Institute of Cardiology. P. Sevak str. 5, Erevan 0044, Republic of Armenia
Armenia


L. G. Tunyan
Research Institute of Cardiology. P. Sevak str. 5, Erevan 0044, Republic of Armenia
Armenia


A. L. Chilingaryan
Research Institute of Cardiology. P. Sevak str. 5, Erevan 0044, Republic of Armenia
Armenia


References

1. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91:265.

2. Melduni R., Cullen M. Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion. J Atr Fibrillation 2012; 5(4): 87-94.

3. Melduni RM, Suri RM, Seward JB, et al. Diastolic dysfunction in patients undergoing cardiac surgery: a pathophysiological mechanism underlying the initiation of new-onset post-operative atrial fibrillation.J Am Coll Cardiol 2011;58:953-61.

4. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007;115:1982-90.

5. Schneider MP, Hua TA, Bohm M et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. JACC 2010;55:2299-307.

6. Dabrowski R, Borowiec A, Smolis-Bak E et al. Effect of combined spironolactone-beta-blocker +/− enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010;106:1609-14.

7. Zile M, Simsic J. Diastolic heart failure: diagnosis and treatment. Clin Cornerstone 2005; 3: 13-24.

8. Doyle J, Ho K, Benefits. Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clin Proc 2009; 84(3): 234-42.

9. Auer J, Weber T, Berent R. Study of Prevention of Postoperative Atrial Fibrillation. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004;147(4): 636-43.

10. Echahidi N, Pibarot P, O'Hara G., Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008: 51; 793-801.

11. Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J Cardiovasc Pharmacol 2006: 8(2): 89-105.

12. Iliuta L., Enache R.. Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Grafting, Perioperative Considerations in Cardiac Surgery. Cardiol Ther 2014; 3(1-2): 13-26.

13. Murat N., Orcan S. et al., Arrhythmic effects of Ivabradine in patients with coronary artery disease. Clin Invest Med 2009; 32 (5): E322-E326.


For citation:


Adamyan K.G., Tunyan L.G., Chilingaryan A.L. Comparative efficacy of amiodarone with ivabradin combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation recurrence in pa- tients with left ventricular diastolic dysfunction. Rational Pharmacotherapy in Cardiology. 2015;11(5):483-488. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-5-483-488

Views: 1889


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)